Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Polaris Group Stories

2014-04-02 16:31:56

SAN DIEGO, April 2, 2014 /PRNewswire/ -- Polaris Group announced today that Shaw T. Chen, M.D., Ph.D. has joined Polaris Pharmaceuticals, Inc. (a subsidiary of Polaris Group) as Executive Vice-President of Regulatory Affairs. Dr. Chen had previously been with the United States (US) Food & Drug Administration (FDA) for over 26 years in new drug development as a primary/supervisory medical staff. His achievements at the FDA included management of new drug review divisions, drafting...

2014-01-27 12:29:29

SAN DIEGO, Jan. 27, 2014 /PRNewswire/ -- Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, acts as a radiosensitizer of pancreatic cancer both in tissue culture and in mice with human pancreatic cancer. These results were presented at the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium in San Francisco, California. The study was performed in conjunction with collaborators at MD Anderson Cancer Center in...

2013-12-02 12:25:46

SAN DIEGO, Dec. 2, 2013 /PRNewswire/ -- Polaris Group announced today that it has filed an Investigational New Drug Application (IND) application with the United States Food and Drug Administration (FDA) to begin Phase 1 clinical trials to test ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of acute myeloid leukemia. The FDA has reviewed this application, waived the 30-day review period and allowed treatment to begin. Polaris Group has previously...

2013-11-06 16:30:47

SAN DIEGO, Nov. 6, 2013 /PRNewswire/ -- Polaris Group announced today that the first patient has been dosed in its Phase 2 trial of ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of Relapsed/Refractory Acute Myeloid Leukemia. Polaris Group is conducting clinical trials on ADI-PEG 20 for the treatment of several other indications, including hepatocellular carcinoma. The latter indication is already in a global Phase 3 study. (Logo:...

2013-10-28 08:28:17

SAN DIEGO, Oct. 28, 2013 /PRNewswire/ -- Polaris Group announced today that positive results from a randomized Phase 2 trial of ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of malignant pleural mesothelioma were presented at the World Conference on Lung Cancer in Sydney, Australia. There were 68 subjects randomized, 44 to ADI-PEG 20 plus best supportive care and 24 to best supportive care only. The target endpoint, enhanced progression...

2013-10-22 12:28:19

SAN DIEGO, Oct. 22, 2013 /PRNewswire/ -- Polaris Group announced today that it has filed an Investigational New Drug Application (IND) application with the United States Food and Drug Administration (FDA) to begin Phase 1 clinical trials to test ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of breast cancer. Polaris Group has previously filed another IND under which it is conducting clinical trials on ADI-PEG 20 for the treatment of multiple...

2013-04-17 12:25:20

Polaris Scientific Colleagues from Several University Cancer Centers Present Data at 2013 AACR Meeting in Washington, DC SAN DIEGO, April 17, 2013 /PRNewswire/ -- Scientists from academic institutions reported at the 2013 annual American Association for Cancer Research meeting, results from preclinical studies which showed that certain bladder cancers and mesotheliomas have metabolic changes and are more likely to respond to treatment with ADI-PEG 20 (pegylated arginine deiminase) if...

2012-06-12 02:26:28

SAN DIEGO, June 12, 2012 /PRNewswire/ -- Scientists from numerous institutions reported at the 2012 annual American Association for Cancer Research meeting, results from preclinical studies which showed that certain sarcomas and bladder cancers are more likely to respond to treatment with ADI-PEG 20 pegylated arginine deiminase) if they are deficient in the enzyme, argininosuccinate synthetase (ASS). This enzyme plays an important role in the synthesis of the amino acid arginine required for...

2012-02-29 09:29:00

SAN DIEGO, Feb. 29, 2012 /PRNewswire/ -- Polaris Group (Polaris) today announced that it has dosed the first patient in a Phase 1 clinical trial evaluating its lead cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in pediatric patients with emphasis on leukemia, lymphoma and sarcoma cancers. These three cancers represent approximately 50% of all cancers that occur in the pediatric population. Patients with advanced cancers who have failed current therapy will be...

2012-01-10 08:00:00

SAN DIEGO, Jan. 10, 2012 /PRNewswire/ -- Polaris Group (Polaris) today announced that it has dosed the first patient in a Phase 1 clinical trial evaluating its lead cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in combination with docetaxel in advanced solid tumors with emphasis on prostate cancer patients. Patients with advanced solid tumors, including castration resistant prostate cancer, who are candidates for docetaxel, will be treated with a standard...